SPRY
$8.89
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
Intraday
Recent News
ARS Pharmaceuticals Q4 Earnings Call Highlights
ARS Pharmaceuticals (NASDAQ:SPRY) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline early commercial progress for neffy, its needle-free epinephrine option for Type I allergic reactions including anaphylaxis, while emphasizing that growth in the category has be
ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ...
ARS Pharmaceuticals Inc (SPRY) reports robust revenue growth and plans for sales force expansion amidst challenges in prescriber workflows and market penetration.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -0.96% and +9.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Recent Regulatory Twists Are Reframing The Story For ARS Pharmaceuticals (SPRY)
Analysts recently nudged their fair value estimate for ARS Pharmaceuticals stock from about US$28.00 to roughly US$28.83 per share, while keeping revenue growth expectations around 45.34% and making only marginal tweaks to the discount rate. The shift reflects a tug of war between bullish views that a competitor’s regulatory setback gives ARS Pharmaceuticals more room to execute, and cautious voices who see higher expectations and ongoing regulatory risk on both sides. Stay with this article...